iSpecimen Inc. (ISPC) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 5.48M USD | Liabilities, Current |
| Cash and equivalents | 4.41M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 21.26K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $5.48M | $4.41M | (m) | $21.26K | (m) | (m) |
| 2026-03-31 | (m) | $5.60M | $2.82M | (m) | $132.85K | (m) | (m) |
| 2025-12-31 | (m) | $6.23M | $6.88M | (m) | $48.30K | (m) | (m) |
| 2025-09-30 | (m) | $5.70M | (m) | (m) | $120.93K | (m) | (m) |
| 2025-06-30 | (m) | $5.17M | (m) | (m) | $372.47K | (m) | (m) |
| 2025-03-31 | (m) | $4.92M | (m) | (m) | $581.65K | (m) | (m) |
| 2024-12-31 | (m) | $5.77M | $1.88M | (m) | $1.44M | (m) | (m) |
| 2024-09-30 | $2.73M | $6.27M | $1.75M | $0.00 | $974.38K | (m) | 0.43× |
| 2024-06-30 | $3.04M | $5.81M | $2.15M | $0.00 | $892.81K | (m) | 0.52× |
| 2024-03-31 | $2.99M | $5.70M | $2.09M | $466.49K | $437.42K | (m) | 0.53× |
| 2023-12-31 | $5.73M | $6.05M | $2.34M | $2.66M | $728.39K | (m) | 0.95× |
| 2023-09-30 | $7.37M | $3.52M | $2.72M | $2.94M | $1.71M | (m) | 2.09× |
| 2023-06-30 | $9.67M | $2.86M | $2.00M | $6.21M | $1.46M | (m) | 3.38× |
| 2023-03-31 | $14.03M | $3.85M | $3.76M | $7.26M | $3.01M | (m) | 3.64× |
| 2022-12-31 | (m) | $4.28M | $15.31M | (m) | $1.60M | (m) | (m) |
| 2022-09-30 | (m) | $2.83M | $20.66M | (m) | $1.78M | (m) | (m) |
| 2022-06-30 | (m) | $2.03M | $23.69M | (m) | $1.66M | (m) | (m) |
| 2022-03-31 | (m) | $2.05M | $26.10M | (m) | $2.36M | (m) | (m) |
| 2021-12-31 | (m) | $2.51M | $27.74M | (m) | $3.00M | (m) | (m) |
| 2021-09-30 | (m) | $2.10M | $9.79M | (m) | $2.72M | (m) | (m) |
| 2021-06-30 | (m) | $5.93M | $13.18M | (m) | $1.99M | (m) | (m) |
| 2020-12-31 | (m) | $22.14M | $695.91K | (m) | $1.53M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |